Bemiparin in neonatal thrombosis: therapeutic dosing and safety.

IF 2.4 3区医学 Q2 OBSTETRICS & GYNECOLOGY

Journal of Perinatology Pub Date : 2024-12-16 DOI:10.1038/s41372-024-02200-1

Maria Sanchez-Holgado, Mercedes Sampedro, Carlos Zozaya, Celia Permuy Romero, Patricia Alvarez-Garcia, Leticia La Banda-Montalvo, Clara Nieto, Adelina Pellicer

{"title":"Bemiparin in neonatal thrombosis: therapeutic dosing and safety.","authors":"Maria Sanchez-Holgado, Mercedes Sampedro, Carlos Zozaya, Celia Permuy Romero, Patricia Alvarez-Garcia, Leticia La Banda-Montalvo, Clara Nieto, Adelina Pellicer","doi":"10.1038/s41372-024-02200-1","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the therapeutic dose and safety of bemiparin in neonatal thrombosis treatment.Study design: A retrospective review was conducted on infants treated with bemiparin between 2018 and 2023 at a tertiary hospital.Results: 72 neonates with a mean gestational age of 37 weeks were included. Twenty were preterm, with a median gestational age of 33.5 weeks and a median birth weight of 1847.5 grams. The mean (SD) initial and therapeutic bemiparin doses were 170.5 (31) and 200 (37.2) IU/kg/day, respectively. Only 32% of patients reached the therapeutic target range (TTR) with the initial dose. Preterm infants required higher doses to reach TTR (215 vs 194.7 IU/kg/day, p = 0.05). Adverse events were minimal (1.4%) and unrelated to the starting dose or prematurity.Conclusion: Bemiparin appears to be a potential therapeutic option for anticoagulation in neonates; however, targeted anti-Xa levels were rarely achieved with the initial dose and most patients required uptitration.","PeriodicalId":16690,"journal":{"name":"Journal of Perinatology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Perinatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41372-024-02200-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the therapeutic dose and safety of bemiparin in neonatal thrombosis treatment.

Study design: A retrospective review was conducted on infants treated with bemiparin between 2018 and 2023 at a tertiary hospital.

Results: 72 neonates with a mean gestational age of 37 weeks were included. Twenty were preterm, with a median gestational age of 33.5 weeks and a median birth weight of 1847.5 grams. The mean (SD) initial and therapeutic bemiparin doses were 170.5 (31) and 200 (37.2) IU/kg/day, respectively. Only 32% of patients reached the therapeutic target range (TTR) with the initial dose. Preterm infants required higher doses to reach TTR (215 vs 194.7 IU/kg/day, p = 0.05). Adverse events were minimal (1.4%) and unrelated to the starting dose or prematurity.

Conclusion: Bemiparin appears to be a potential therapeutic option for anticoagulation in neonates; however, targeted anti-Xa levels were rarely achieved with the initial dose and most patients required uptitration.

查看原文本刊更多论文

研究目的评估贝美肝素在新生儿血栓治疗中的治疗剂量和安全性：对2018年至2023年间在一家三级医院接受贝美肝素治疗的婴儿进行回顾性研究：共纳入72名新生儿，平均胎龄为37周。其中 20 例为早产儿，中位胎龄为 33.5 周，中位出生体重为 1847.5 克。贝美肝素的初始剂量和治疗剂量的平均值（标度）分别为 170.5（31）和 200（37.2）IU/kg/天。只有 32% 的患者的初始剂量达到了治疗目标范围 (TTR)。早产儿需要更高的剂量才能达到治疗目标范围（215 对 194.7 IU/kg/天，p = 0.05）。不良反应极少（1.4%），且与起始剂量或早产无关：结论：贝美肝素似乎是新生儿抗凝的一种潜在治疗选择；然而，初始剂量很少能达到目标抗 Xa 水平，大多数患者需要增加剂量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Perinatology 医学-妇产科学

CiteScore

5.40

自引率

6.90%

发文量

284

审稿时长

3-8 weeks

期刊介绍： The Journal of Perinatology provides members of the perinatal/neonatal healthcare team with original information pertinent to improving maternal/fetal and neonatal care. We publish peer-reviewed clinical research articles, state-of-the art reviews, comments, quality improvement reports, and letters to the editor. Articles published in the Journal of Perinatology embrace the full scope of the specialty, including clinical, professional, political, administrative and educational aspects. The Journal also explores legal and ethical issues, neonatal technology and product development. The Journal’s audience includes all those that participate in perinatal/neonatal care, including, but not limited to neonatologists, perinatologists, perinatal epidemiologists, pediatricians and pediatric subspecialists, surgeons, neonatal and perinatal nurses, respiratory therapists, pharmacists, social workers, dieticians, speech and hearing experts, other allied health professionals, as well as subspecialists who participate in patient care including radiologists, laboratory medicine and pathologists.